RDHL

Redhill Biopharma Ltd.

0.69 USD

Last updated Sep 12, 02:19 UTC

Yesterday HIGH

$0.7

Yesterday LOW

$0.65

52w HIGH

$2.79

52w LOW

$0.57

EPS

0.00

PE

0.00

Next Earnings

Sep 22, 2026

Overview News Government Trades Fundamentals

Redhill Biopharma Ltd. stock is up 15.53% since 30 days ago. The next earnings date is Sep 22, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 13 September’s closed higher than August.

Benzinga Insights

Thu Jun 11, 2026

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Newsdesk

Tue Jun 9, 2026

RedHill Biopharma shares are trading lower. The company announced the FDA has granted rare pediatric disease designation to opaganib for treatment of neuroblastoma.
Benzinga Insights

Tue Jun 9, 2026

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Newsdesk

Tue Jun 9, 2026

Redhill Biopharma Announces FDA Rare Pediatric Disease Designation For Opaganib For The Treatment Of Neuroblastoma

The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most commonly affecting babies and young children--Rare
Benzinga Newsdesk

Fri Jun 5, 2026

U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts

https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
Benzinga Newsdesk

Wed Jun 3, 2026

RedHill Biopharma Engages WHO Solidarity Platform And Pharma Partners To Advance Opaganib As Oral Host Directed Therapy For Ebola Virus Disease Amid Bundibugyo Outbreak Showing Preclinical Filovirus Activity And Prior Phase 3 Antiviral Results

Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing
Benzinga Newsdesk

Tue Jun 2, 2026

RedHill Biopharma Actively Discussing Potential Collaborations For Advancement Of Its Investigational Oral Drug, Opaganib, To Combat Ebola Virus Disease

Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential
Benzinga Newsdesk

Thu Apr 30, 2026

Redhill Biopharma Announces New In Vitro Testing Results Demonstrating RHB-204's Comparability To RHB-104 In Mycobacterium Avium Subspecies Paratuberculosis Killing Efficacy

RHB-2041 is a next-generation optimized formulation of RedHill's oral RHB-1042, designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking Mycobacterium avium subspecies
Benzinga Newsdesk

Mon Apr 27, 2026

Redhill Biopharma FY EPS $0.00, Sales $286.000K Down From $8.043M YoY

Redhill Biopharma (NASDAQ:RDHL) reported quarterly earnings of $0.00 per share. The company reported $286.000 thousand in sales this quarter. This is a 96.44 percent decrease over sales of $8.043 million the same period
Benzinga Newsdesk

Wed Apr 22, 2026

RedHill Presents New Preclinical Showing Effects Of Opaganib As Potential Add-On Therapy In Models Of Retinoblastoma And Triple-Negative Breast Cancer At AACR Annual Meeting.

New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of opaganib[1] as potential add-on therapy in models of

VOO $702.77 USD

GS $1,029.08 USD

GTBIF GTBIF $0.00 USD

IBM $243.12 USD

AZN $160.12 USD

CSCO $112.19 USD

LHX $245.54 USD

COST $904.77 USD